Spread of Escherichia coli Strains with High-Level Cefotaxime and Ceftazidime Resistance between the Community, Long-Term Care Facilities, and Hospital Institutions

ABSTRACT A total of 151 Escherichia coli strains resistant to cefotaxime and ceftazidime were isolated during a prospective surveillance study. These strains were characterized by clinical, microbiological, and molecular analyses and were distributed into four clusters of 103, 11, 6, and 5 isolates, along with 25 unrelated strains. The principal cluster was isolated from urine, wound, blood, and other samples in three hospitals, eight nursing homes, and a community healthcare center. This cluster was associated with both nosocomial (65%) and community-acquired (35%) infections. Most strains were resistant to ciprofloxacin, gentamicin, tobramycin, cefepime, amoxicillin-clavulanic acid, and trimethoprim-sulfamethoxazole but were susceptible to imipenem. All isolates from the four clusters expressed the extended-spectrum β-lactamase (ESBL) CTX-M-15. This enzyme was also present in 8 (30.8%) of the 26 unrelated isolates. The other ESBLs, CTX-M-14 and CTX-M-32, were detected in five and seven cases, respectively, but they were detected in individual E. coli isolates only. In three clusters, blaCTX-M-15 alleles were linked to an ISEcp1-like element, while in eight strains of cluster II an IS26 element preceded the blaCTX-M-15 allele. An additional pool of resistance genes included tetA, drfA14 or dfrA17, sul1 or sul2, aac(6′)Ib, and aac(3)IIb. All except one of the 27 isolates tested for genetic virulence markers harbored the same three virulence genes: iutA and fyuA (siderophores), and traT (serum survival factor). Epidemic or occasional isolates of cefotaxime- and ceftazidime-resistant E. coli can spread between distinct health facilities including hospitals, community health centers, and long-term care centers.

[1]  S. Huovinen.  Rapid isoelectric focusing of plasmid-mediated beta-lactamases with Pharmacia PhastSystem , 1988, Antimicrobial Agents and Chemotherapy.

[2]  D. Livermore.  beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.

[3]  J. R. Johnson,et al.  Extended virulence genotypes of Escherichia coli strains from patients with urosepsis in relation to phylogeny and host compromise. , 2000, The Journal of infectious diseases.

[4]  J. Barbé,et al.  Cloning and Sequence of the Gene Encoding a Novel Cefotaxime-Hydrolyzing b-Lactamase (CTX-M-9) from Escherichia coli in Spain , 2000 .

[5]  J. Barbé,et al.  Cloning and Sequence of the Gene Encoding a Novel Cefotaxime-Hydrolyzing β-Lactamase (CTX-M-9) fromEscherichia coli in Spain , 2000, Antimicrobial Agents and Chemotherapy.

[6]  A. Oliver,et al.  Characterization of Clinical Isolates ofKlebsiella pneumoniae from 19 Laboratories Using the National Committee for Clinical Laboratory Standards Extended-Spectrum β-Lactamase Detection Methods , 2001, Journal of Clinical Microbiology.

[7]  L. Ng,et al.  Multiplex PCR for the detection of tetracycline resistant genes. , 2001, Molecular and cellular probes.

[8]  J. M. Kim,et al.  The prevalence of trimethoprim-resistance-conferring dihydrofolate reductase genes in urinary isolates of Escherichia coli in Korea. , 2001, The Journal of antimicrobial chemotherapy.

[9]  S. Levy,et al.  Genetic Characterization of Highly Fluoroquinolone-Resistant Clinical Escherichia coli Strains from China: Role ofacrR Mutations , 2001, Antimicrobial Agents and Chemotherapy.

[10]  P. Nordmann,et al.  Plasmid-mediated extended-spectrum beta-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. , 2001, FEMS microbiology letters.

[11]  B. Willey,et al.  Outbreaks of multi-drug resistant Escherichia coli in long-term care facilities in the Durham, York and Toronto regions of Ontario, 2000-2002. , 2002, Canada communicable disease report = Releve des maladies transmissibles au Canada.

[12]  P. Nordmann,et al.  Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3 , 2002 .

[13]  C. Torres,et al.  β-Lactamases in Ampicillin-Resistant Escherichia coli Isolates from Foods, Humans, and Healthy Animals , 2002, Antimicrobial Agents and Chemotherapy.

[14]  J. Gerberding,et al.  Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit: risk factors for infection and colonization. , 2003, The Journal of hospital infection.

[15]  A. Hossain,et al.  Discovery of CTX-M-Like Extended-Spectrum β-Lactamases in Escherichia coli Isolates from Five U.S. States , 2003, Antimicrobial Agents and Chemotherapy.

[16]  Gianfranco Amicosante,et al.  Multiple CTX-M-Type Extended-Spectrum β-Lactamases in Nosocomial Isolates of Enterobacteriaceae from a Hospital in Northern Italy , 2003, Journal of Clinical Microbiology.

[17]  M. Kuskowski,et al.  Phylogenetic origin and virulence genotype in relation to resistance to fluoroquinolones and/or extended-spectrum cephalosporins and cephamycins among Escherichia coli isolates from animals and humans. , 2003, The Journal of infectious diseases.

[18]  G. Barnaud,et al.  Dissemination of CTX-M-Type β-Lactamases among Clinical Isolates of Enterobacteriaceae in Paris, France , 2004, Antimicrobial Agents and Chemotherapy.

[19]  G. Bou,et al.  High-Level Resistance to Ceftazidime Conferred by a Novel Enzyme, CTX-M-32, Derived from CTX-M-1 through a Single Asp240-Gly Substitution , 2004, Antimicrobial Agents and Chemotherapy.

[20]  F. Baquero,et al.  Dramatic Increase in Prevalence of Fecal Carriage of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae during Nonoutbreak Situations in Spain , 2004, Journal of Clinical Microbiology.

[21]  N. Høiby,et al.  Cefotaximases (CTX-M-ases), an expanding family of extended-spectrum β-lactamases , 2004 .

[22]  N. Høiby,et al.  Cefotaximases (CTX-M-ases), an expanding family of extended-spectrum beta-lactamases. , 2004, Canadian journal of microbiology.

[23]  E. Bingen,et al.  Emergence and Spread of Three Clonally Related Virulent Isolates of CTX-M-15-Producing Escherichia coli with Variable Resistance to Aminoglycosides and Tetracycline in a French Geriatric Hospital , 2004, Antimicrobial Agents and Chemotherapy.

[24]  M. Kaufmann,et al.  Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. , 2004, The Journal of antimicrobial chemotherapy.

[25]  R. Bonnet.  Growing Group of Extended-Spectrum β-Lactamases: the CTX-M Enzymes , 2004, Antimicrobial Agents and Chemotherapy.

[26]  J. Rodríguez-Baño,et al.  Epidemiology and Clinical Features of Infections Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Nonhospitalized Patients , 2004, Journal of Clinical Microbiology.

[27]  M. Gardam,et al.  Complete Nucleotide Sequence of a 92-Kilobase Plasmid Harboring the CTX-M-15 Extended-Spectrum Beta-Lactamase Involved in an Outbreak in Long-Term-Care Facilities in Toronto, Canada , 2004, Antimicrobial Agents and Chemotherapy.

[28]  Z. Daoud,et al.  Countrywide Spread of Community- and Hospital-Acquired Extended-Spectrum β-Lactamase (CTX-M-15)-Producing Enterobacteriaceae in Lebanon , 2005, Journal of Clinical Microbiology.

[29]  G. Kronvall,et al.  Integrons and gene cassettes in clinical isolates of co-trimoxazole-resistant Gram-negative bacteria. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[30]  J. Campos,et al.  Antimicrobial-resistant Invasive Escherichia coli, Spain , 2005, Emerging infectious diseases.

[31]  P. Coll,et al.  Surveillance of extended-spectrum beta-lactamases from clinical samples and faecal carriers in Barcelona, Spain. , 2005, The Journal of antimicrobial chemotherapy.

[32]  V. Miriagou,et al.  Emergence of CTX-M-15-Producing Enterobacteria in Cameroon and Characterization of a blaCTX-M-15-Carrying Element , 2005, Antimicrobial Agents and Chemotherapy.

[33]  L. Martínez-Martínez,et al.  Nationwide Study of Escherichia coli and Klebsiella pneumoniae Producing Extended-Spectrum β-Lactamases in Spain , 2005, Antimicrobial Agents and Chemotherapy.

[34]  P. Wayne.  PERFORMANCE STANDARDS FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING, NINTH INFORMATIONAL SUPPLEMENT , 2008 .